AKEBIA THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
AKEBIA THERAPEUTICS, INC. (AKBA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $4.20 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-03-13
- AKEBIA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $4.20M, a 0.50% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $4.22M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|
| 2024-12-31 | $4.20M 10-K · filed 2025-03-13 | |
| 2023-12-31 | $4.22M 10-K · filed 2025-03-13 | |
| 2020-06-30 | -$1.16M 10-Q · filed 2020-08-10 | |
| 2019-06-30 | -$1.10M 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |